跳至主要内容
临床试验/JPRN-UMIN000000713
JPRN-UMIN000000713已完成未知

Efficacy of PEG-IFN alfa-2b plus Ribabirin and HMG-CoA reductase inhibitor combination antiviral therapy ; pilot study - Efficacy of PEG-IFN alfa-2b plus Ribabirin and HMG-CoA reductase inhibitor combination therapy

Hiroshima liver study group0 个研究点目标入组 10 人开始时间: 2007年5月9日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients receiving shosaiko-to 2) Autoimmune hepatitis 3) History of hypersensitivity to PEG-IFN alpha-2b or other interferons 4) History of hypersensitivity to biological products such as vaccine 5) Decompenstated liver cirrhosis 6) HCC, malignat tumor 7) With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 8) Pregnant or lactating women and women who may be pregnant 9) Judged by investigator not to be appropriate for inclusion in this study

研究者

发起方
Hiroshima liver study group

相似试验